Abstract
BACKGROUND. The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented. METHODS. The outcome of 420 patients with CML post-imatinib failure (resistance-recurrence in 374; toxicities in 46) were reviewed in relation to survival, overall, and by different therapies. RESULTS. The estimated 3-year survival rates were 72% in 88 patients who progressed in chronic phase, 30% in 130 patients who progressed in accelerated phase, 7% in 156 patients who progressed in blastic phase, and 75% in 37 patients in chronic phase with imatinib intolerance. Survival in chronic phase was better when subsequent therapy was nilotinib or dasatinib vs allogeneic stem cell transplant vs others (estimated 2-year survival rates 100% vs 72% vs 67%; P = .01), but not in accelerated-blastic phase. CONCLUSIONS. Prognosis post-imatinib failure in chronic phase is reasonable; it is poor if the CML phase post-imatinib failure is accelerated or blastic.
Original language | English (US) |
---|---|
Pages (from-to) | 1556-1560 |
Number of pages | 5 |
Journal | Cancer |
Volume | 109 |
Issue number | 8 |
DOIs | |
State | Published - Apr 15 2007 |
Externally published | Yes |
Keywords
- Chronic myelogenous leukemia
- Imatinib mesylate failure
- Prognosis
ASJC Scopus subject areas
- Oncology
- Cancer Research